Published in Cell Res on April 01, 2005
Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A (2006) 1.95
14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol (2011) 1.65
14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J (2006) 1.40
An obligatory heterodimer of 14-3-3beta and 14-3-3epsilon is required for aldosterone regulation of the epithelial sodium channel. J Biol Chem (2008) 1.12
The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. J Struct Funct Genomics (2007) 1.07
Structure of a 14-3-3σ-YAP phosphopeptide complex at 1.15 A resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 1.04
14-3-3 phosphoprotein interaction networks - does isoform diversity present functional interaction specification? Front Plant Sci (2012) 0.97
The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming. Nat Commun (2015) 0.90
Structural basis for the 14-3-3 protein-dependent inhibition of the regulator of G protein signaling 3 (RGS3) function. J Biol Chem (2011) 0.85
Critical residue that promotes protein dimerization: a story of partially exposed Phe25 in 14-3-3σ. J Chem Inf Model (2011) 0.84
14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Lett (2007) 0.82
14-3-3zeta/tau heterodimers regulate Slingshot activity in migrating keratinocytes. Biochem Biophys Res Commun (2009) 0.82
Insight into conformational change for 14-3-3σ protein by molecular dynamics simulation. Int J Mol Sci (2014) 0.82
Structural Analysis of the 14-3-3ζ/Chibby Interaction Involved in Wnt/β-Catenin Signaling. PLoS One (2015) 0.79
Electrostatic interactions play a minor role in the binding of ExoS to 14-3-3 proteins. Biochem J (2010) 0.78
14-3-3σ Gene Loss Leads to Activation of the Epithelial to Mesenchymal Transition Due to the Stabilization of c-Jun Protein. J Biol Chem (2016) 0.77
Protein modifications regulate the role of 14-3-3γ adaptor protein in cAMP-induced steroidogenesis in MA-10 Leydig cells. J Biol Chem (2014) 0.77
Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using Limited Proteolysis. J Proteome Res (2016) 0.76
Molecular Characterization of the 14-3-3 Gene Family in Brachypodium distachyon L. Reveals High Evolutionary Conservation and Diverse Responses to Abiotic Stresses. Front Plant Sci (2016) 0.76
Loss of the 14-3-3σ is essential for LASP1-mediated colorectal cancer progression via activating PI3K/AKT signaling pathway. Sci Rep (2016) 0.76
Identification of Novel 14-3-3 Residues That Are Critical for Isoform-specific Interaction with GluN2C to Regulate N-Methyl-D-aspartate (NMDA) Receptor Trafficking. J Biol Chem (2015) 0.76
Crystal structure of the Leishmania major MIX protein: a scaffold protein that mediates protein-protein interactions. Protein Sci (2011) 0.75
Deletion of 14-3-3σ sensitizes mice to DMBA/TPA-induced papillomatosis. Oncotarget (2016) 0.75
Lifeact: a versatile marker to visualize F-actin. Nat Methods (2008) 12.23
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
MicroRNA-34a regulates cardiac ageing and function. Nature (2013) 4.03
Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A (2002) 3.55
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle (2011) 3.15
Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci (2006) 2.79
Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res (2005) 2.37
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle (2009) 2.11
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A (2011) 1.90
Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch (2011) 1.72
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle (2008) 1.71
Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure (2013) 1.63
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics (2011) 1.59
Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics (2005) 1.57
Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle (2007) 1.55
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 1.52
AP4 encodes a c-MYC-inducible repressor of p21. Proc Natl Acad Sci U S A (2008) 1.45
Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget (2013) 1.43
Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell Cycle (2007) 1.39
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Expansion of the genetic code enables design of a novel "gold" class of green fluorescent proteins. J Mol Biol (2003) 1.34
Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc (2011) 1.30
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl (2011) 1.30
Practical aspects of the 2D 15N-[1h]-NOE experiment. J Biomol NMR (2002) 1.29
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem (2008) 1.27
c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle (2007) 1.25
Protein folding and stability of human CDK inhibitor p19(INK4d). J Mol Biol (2002) 1.25
Protein solubility: sequence based prediction and experimental verification. Bioinformatics (2006) 1.23
Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res (2012) 1.21
AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med (2013) 1.19
Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. Structure (2002) 1.15
Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res (2002) 1.13
Epigenetic silencing of 14-3-3sigma in cancer. Semin Cancer Biol (2006) 1.13
Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J Biol Chem (2005) 1.12
Molecular structure of the rod domain of dictyostelium filamin. J Mol Biol (2004) 1.12
The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res (2005) 1.11
Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A (2006) 1.11
Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest (2003) 1.10
Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem (2007) 1.09
c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem (2008) 1.09
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med (2005) 1.09
SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J (2013) 1.09
The c-MYC-AP4-p21 cascade. Cell Cycle (2009) 1.08
Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene (2004) 1.08
Backbone dynamics of green fluorescent protein and the effect of histidine 148 substitution. Biochemistry (2003) 1.08
Role of the ubiquitin-like protein Hub1 in splice-site usage and alternative splicing. Nature (2011) 1.07
Characterization of 14-3-3sigma dimerization determinants: requirement of homodimerization for inhibition of cell proliferation. Cell Cycle (2006) 1.07
1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des (2010) 1.07
Shugoshin is a Mad1/Cdc20-like interactor of Mad2. EMBO J (2011) 1.06
Induction of cullin 7 by DNA damage attenuates p53 function. Proc Natl Acad Sci U S A (2007) 1.06
Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene (2003) 1.04
p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res (2013) 1.03
Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. J Comb Chem (2010) 1.03
Slow exchange in the chromophore of a green fluorescent protein variant. J Am Chem Soc (2002) 1.02
DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum (2007) 1.02
Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem (2011) 1.01
Structures of actin-bound Wiskott-Aldrich syndrome protein homology 2 (WH2) domains of Spire and the implication for filament nucleation. Proc Natl Acad Sci U S A (2010) 1.00
Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest (2002) 1.00
DNA-binding properties of the recombinant high-mobility-group-like AT-hook-containing region from human BRG1 protein. Biol Chem (2006) 0.99
The p53/microRNA network in cancer: experimental and bioinformatics approaches. Adv Exp Med Biol (2013) 0.99
Structure of the N-terminal domain of the FOP (FGFR1OP) protein and implications for its dimerization and centrosomal localization. J Mol Biol (2006) 0.99
Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Am Chem Soc (2005) 0.96
Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol (2005) 0.96
Roles of small laccases from Streptomyces in lignin degradation. Biochemistry (2014) 0.95
Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A (2012) 0.95
Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure (2005) 0.95
Robust NMR screening for lead compounds using tryptophan-containing proteins. J Am Chem Soc (2009) 0.95
A novel medium for expression of proteins selectively labeled with 15N-amino acids in Spodoptera frugiperda (Sf9) insect cells. J Biomol NMR (2003) 0.95
Functional and structural characterization of Spl proteases from Staphylococcus aureus. J Mol Biol (2006) 0.95
An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem (2007) 0.94
Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res (2010) 0.93
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat (2013) 0.91
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl (2014) 0.91
Ablation of cyclase-associated protein 2 (CAP2) leads to cardiomyopathy. Cell Mol Life Sci (2012) 0.91
Structure of the N-terminal domain of the adenylyl cyclase-associated protein (CAP) from Dictyostelium discoideum. Structure (2003) 0.89
The three-dimensional structures of tick carboxypeptidase inhibitor in complex with A/B carboxypeptidases reveal a novel double-headed binding mode. J Mol Biol (2005) 0.88
MiR-34a and p53. Cell Cycle (2009) 0.88